October 24, 2016 04:05 PM EDT
Pharma

FDA clears Glob­al Blood Ther­a­peu­tics to fo­cus on key bio­mark­er in piv­otal sick­le cell tri­al

John Carroll

Editor & Founder

Just days af­ter flesh­ing out its lat­est set of pos­i­tive da­ta from a tiny study of GBT440 for sick­le cell dis­ease, Glob­al Blood Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times